Literature DB >> 20951741

New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.

D Fanoni1, S Tavecchio, S Recalcati, Y Balice, L Venegoni, R Fiorani, C Crosti, E Berti.   

Abstract

Reactivities of the monoclonal antibodies (mAbs) of the 9th Human Leukocyte Differentiation Antigen Workshop, in order to define specific antigenic expression of the primary cutaneous B-cell lymphomas (PC-BCL), were analyzed by immunohistology on human tonsil and on PC-BCL, such as follicular centre B-cell lymphomas (FCL), marginal zone lymphomas (MZL) and diffuse large B-cells lymphomas leg-type (DLBL-LT). We identified some subgroups of mAbs that were exclusively or preferentially positive in one lymphoma cell type: the PC-FCL subgroup of mAbs includes PD1/CD279, GCET-1, hFCRL1/CD307a, FCRL2/CD307b, CXCR5/CD185, B7-DC/CD273, MRC/CD200, CD130, CXCR4/CD184, Siglec-5/14, CD150, on the other hand subgroup of mAbs in PC-MZL includes BTLA/CD272, BLIMP-1, hCD38. No specific subgroup of mAbs was found to label PC-DLBCL. This study may be useful to better define specific antigen profile of different PC-BCL entities leading to a correct diagnosis.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951741     DOI: 10.1016/j.imlet.2010.09.022

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  34 in total

Review 1.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

2.  Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas.

Authors:  Shingo Inaguma; Jerzy Lasota; Zengfeng Wang; Anna Felisiak-Golabek; Hiroshi Ikeda; Markku Miettinen
Journal:  Mod Pathol       Date:  2016-11-04       Impact factor: 7.842

3.  Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.

Authors:  Shingo Inaguma; Zengfeng Wang; Jerzy Lasota; Maarit Sarlomo-Rikala; Peter A McCue; Hiroshi Ikeda; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2016-08       Impact factor: 6.394

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 5.  B lymphocytes and cancer: a love-hate relationship.

Authors:  Grace J Yuen; Ezana Demissie; Shiv Pillai
Journal:  Trends Cancer       Date:  2016-12

6.  Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.

Authors:  Hailong Zhu; Huali Qin; Ziling Huang; Shuai Li; Xuyou Zhu; Jian He; Jing Yang; Xiaoting Yu; Xianghua Yi
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

7.  Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.

Authors:  Shingo Inaguma; Jerzy Lasota; Zengfeng Wang; Piotr Czapiewski; Renata Langfort; Janusz Rys; Joanna Szpor; Piotr Waloszczyk; Krzysztof Okoń; Wojciech Biernat; Hiroshi Ikeda; David S Schrump; Raffit Hassan; Markku Miettinen
Journal:  Hum Pathol       Date:  2017-08-12       Impact factor: 3.466

Review 8.  Immunotherapy for lung cancer: for whom the bell tolls?

Authors:  Pedro Madureira; Ramon Andrade de Mello; Alessandro de Vasconcelos; Yan Zhang
Journal:  Tumour Biol       Date:  2015-03-04

Review 9.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

10.  Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.

Authors:  Zhao Yang; Rong Yu; Wei Deng; Weihu Wang
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-29       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.